Prognostic Analysis of Local Advanced Cervical Cancer After Neoadjuvant Chemotherapy
Department of Gynaecology and Obstetrics, First Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China
| Abstract: | Background: This study aims to analyze the factors influencing the survival and prognosis of patients with locally advanced cervical cancer (LACC) after neoadjuvant chemotherapy (NACT), so as to provide theoretical guidance for clinical work. Methods: A total of 263 patients diagnosed with stage IB3, IIA2, IIB and IIIC1r cervical cancer according to FIGO 2018 criteria were enrolled in this retrospective study. They were admitted to First Affiliated Hospital of Chongqing Medical University from January 2018 to December 2021. After receiving 1-4 cycles of "platinum + paclitaxel" chemotherapy and effective NACT, the patients accepted surgery including radical hysterectomy and pelvic lymph node dissection. All patients with one of high-risk factors or two of medium-risk factors are exposed to additional radiation according to post-operative pathological risk factors. Patients were divided into two parts based on whether or not radiotherapy was supplemented after surgery. The baseline characteristics, treatment plan, pathological characteristics and survival prognosis of the two groups were compared in this study. The main endpoint of the study was recurrence or death within 2 years. The 2-year progression-free survival (PFS) rate was compared between the two groups in order to analyze the risk factors affecting prognosis. Results: In this study, 59 patients without supplemental radiotherapy and 204 patients with supplemental radiotherapy were included. The 2-year PFS rate was 98.10% and 98.90% respectively (p=0.606) in the group with and without supplementary radiotherapy. Univariate analysis showed that parastatal infiltration and lympho-vascular space infiltration were risk factors for 2-year PFS, while multivariate analysis showed that only lympho-vascular space infiltration was independent risk factor for PFS. Conclusion: In conclusion, NACT can also reduce the occurrence of radiotherapy in addition to obtaining the opportunity of surgery, so as to improve the quality of life of patients without affecting survival. Meanwhile, LVSI is an independent risk factor for progression-free survival in patients with locally advanced cervical cancer who receive NACT. For such patients, complementary treatment after surgery is more helpful to ensure prognosis. |
| Keywords: | Cervical Squamous Cell Carcinoma; Neoadjuvant Chemotherapy; Radical Surgery |
| DOI: | 10.57237/j.cmf.2023.02.001 |
View:
Downloads:
收稿日期: 2023-03-22
接受日期: 2023-07-06
在线出版日期: 2023-07-24
参考文献
| [1] | Bhattacharjee R, Das S S, Biswal S S, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies [J]. Crit Rev Oncol Hematol, 2022, 174: 103675. DOI: 10.1016/j.critrevonc.2022.103675. |
| [2] | Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71 (3): 209-249. DOI: 10.3322/caac.21660. |
| [3] | Poddar P, Maheshwari A. Surgery for cervical cancer: consensus & controversies [J]. Indian J Med Res, 2021, 154 (2): 284-292. DOI: 10.4103/ijmr.IJMR_4240_20. |
| [4] | Rahangdale L, Mungo C, O'Connor S, et al. Human papillomavirus vaccination and cervical cancer risk [J]. BMJ, 2022, 379: e70115. DOI: 10.1136/bmj-2022-070115. |
| [5] | Zeng J, Sun P, Ping Q, et al. Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy [J]. PLoS One, 2022, 17 (3): e266001. DOI: 10.1371/journal.pone.0266001. |
| [6] | Gadducci A, Cosio S. Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research [J]. Anticancer Res, 2020, 40 (9): 4819-4828. DOI: 10.21873/anticanres.14485. |
| [7] | Li J, Li Y, Wang H, et al. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer [J]. BMC Cancer, 2023, 23 (1): 51. DOI: 10.1186/s12885-023-10517-x. |
| [8] | Hu Y, Han Y, Shen Y, et al. Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial [J]. BMC Cancer, 2022, 22 (1): 1270. DOI: 10.1186/s12885-022-10355-3. |
| [9] | Mousavi A, Modarres G M, Akhavan S, et al. The Outcome of Locally Advanced Cervical Cancer in Patients Treated with Neoadjuvant Chemotherapy Followed by Radical Hysterectomy and Primary Surgery [J]. Iran J Med Sci, 2021, 46 (5): 355-363. DOI: 10.30476/ijms.2020.81973.0. |
| [10] | Huang Y, Chen L, Cai J, et al. Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer [J]. World J Surg Oncol, 2022, 20 (1): 264. DOI: 10.1186/s12957-022-02731-x. |
| [11] | Lei J, Arroyo-Mühr L S, Lagheden C, et al. Human Papillomavirus Infection Determines Prognosis in Cervical Cancer [J]. J Clin Oncol, 2022, 40 (14): 1522-1528. DOI: 10.1200/JCO.21.01930. |
| [12] | Kuno I, Takayanagi D, Asami Y, et al. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer [J]. Sci Rep, 2021, 11 (1): 19261. DOI: 10.1038/s41598-021-98527-2. |
| [13] | Xu X, Feng T, Li D, et al. Prevalent distribution and survival outcome of HPV infection in patients with early-stage cervical cancer in Hangzhou, China [J]. BMC Infect Dis, 2022, 22 (1): 941. DOI: 10.1186/s12879-022-07888-0. |
| [14] | Shen Z, Qu A, Jiang P, et al. Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review [J]. Curr Oncol, 2022, 29 (8): 5262-5277. DOI: 10.3390/curroncol29080418. |
| [15] | Mohamud A, Høgdall C, Schnack T. Prognostic value of the 2018 FIGO staging system for cervical cancer [J]. Gynecol Oncol, 2022, 165 (3): 506-513. DOI: 10.1016/j.ygyno.2022.02.017. |
| [16] | Li J, Luo J, Liu G, et al. Influencing factors and risk prediction model for cervical cancer recurrence [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2022, 47 (12): 1711-1720. DOI: 10.11817/j.issn.1672-7347.2022.210722. |
| [17] | He J, Zhuang Y, Hu C. Clinicopathological characteristics and prognostic risk factors of cervical cancer patients aged ≤ 35 years old [J]. Medicine (Baltimore), 2022, 101 (50): e32004. DOI: 10.1097/MD.0000000000032004. |
| [18] | Olthof E P, Mom C H, Snijders M, et al. The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer [J]. Acta Obstet Gynecol Scand, 2022, 101 (5): 550-557. DOI: 10.1111/aogs.14316. |
| [19] | Ota N, Yoshimoto Y, Darwis N D M, et al. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy [J]. Japanese Journal of Radiology, 2022, 40 (5): 534-541. DOI: 10.1007/s11604-021-01230-5. |
| [20] | Liang Y, Yu M, Zhou C, et al. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy [J]. Diagnostic Pathology, 2020, 15 (1). DOI: 10.1186/s13000-020-00977-1. |
| [21] | Nishio S, Yonemori K, Usami T, et al. Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826 [J]. Cancer Sci, 2022, 113 (11): 3877-3887. DOI: 10.1111/cas.15479. |
